What We propose to engineer structural elements into the UTRs of messenger RNA (mRNA) that interact with proteins that are overexpressed in cancer cells to induce the translation of the exogenous therapeutic mRNA. Why mRNA therapies are being explored for use in vaccines for viral and bacterial infections as well as personalized cancer vaccines, where the mRNA contains the code to produce an antigen to train the immune system against these diseases. Current mRNA therapies use UTRs from Beta-globin mRNA which are associated with accumulation of the antigens in unwanted cell-types and off-target effects. Therefore, with this project I aim to design and construct new mRNAs which allows for cell-specific delivery and translation of our therapeutic mRNA and reduces off-target effects. How To achieve these goals, I will implement unique RNA motifs into the UTRs of mRNA that binds to cancer biomarkers such as human antigen R (HuR). Cell specific delivery and translation efficacy of these novel mRNA constructs will be evaluated by fluorescent-based reporter assays in cancer and primary cell lines.